Ajax Therapeutics: $95 Million Raised To Develop Next-Gen JAK Inhibitors For Patients With MPNs
By Amit Chowdhry ● May 21, 2024
Ajax Therapeutics, a biopharmaceutical company developing next-generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), announced the closing of an oversubscribed $95 million Series C funding round. The funding was led by Goldman Sachs Alternatives with participation by Eli Lilly and Company, Vivo Capital, RA Capital Management, Point72 and existing investors EcoR1 Capital, Boxer Capital, Schrödinger, Inc. and Inning One Ventures. In connection with the funding, Amit Sinha, Head of Life Sciences Investing, and Ming Cheah, PhD, Vice President of Life Sciences Investing at Goldman Sachs Alternatives, joined Ajax’s board of directors.